Document Detail

Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease.
MedLine Citation:
PMID:  20566765     Owner:  NLM     Status:  MEDLINE    
We have evaluated the clinical efficacy of the combination of oral rifampin at 10 mg/kg of body weight and intramuscular streptomycin at 15 mg/kg for 8 weeks (RS8), as recommended by the WHO, in 160 PCR-confirmed cases of Mycobacterium ulcerans disease. In 152 patients (95%) with all forms of disease from early nodules to large ulcers, with or without edema, the lesions healed without recourse to surgery. Eight patients whose ulcers were healing poorly had skin grafting after completion of antibiotics. There were no recurrences among 158 patients reviewed at the 1-year follow-up. The times to complete healing ranged from 2 to 48 weeks, according to the type and size of the lesion, but the average rate of healing (rate of reduction in ulcer diameter) varied widely. Thirteen subjects had positive cultures for M. ulcerans during or after treatment, but all the lesions healed without further antibiotic treatment. Adverse events were rare. These results confirm the efficacy of RS8 delivered in a community setting.
Fred Stephen Sarfo; Richard Phillips; Kingsley Asiedu; Edwin Ampadu; Nana Bobi; E Adentwe; Awuli Lartey; Ishmael Tetteh; M Wansbrough-Jones
Related Documents :
7439625 - Primary carcinoma of the remnant stomach--report of three cases.
19437575 - Successful use of adalimumab for treating fistulizing crohn's disease with pyoderma gan...
19128245 - Autologous platelet-rich fibrin matrix as cell therapy in the healing of chronic lower-...
2949775 - Treatment of mooren's ulcer with cyclosporin a: report of three cases.
19332185 - Rationale, design, and governance of prospective randomized evaluation of celecoxib int...
15710575 - Home-treatment of deep vein thrombosis in patients with cancer.
Publication Detail:
Type:  Clinical Trial; Journal Article     Date:  2010-06-21
Journal Detail:
Title:  Antimicrobial agents and chemotherapy     Volume:  54     ISSN:  1098-6596     ISO Abbreviation:  Antimicrob. Agents Chemother.     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-08-18     Completed Date:  2010-12-01     Revised Date:  2014-08-12    
Medline Journal Info:
Nlm Unique ID:  0315061     Medline TA:  Antimicrob Agents Chemother     Country:  United States    
Other Details:
Languages:  eng     Pagination:  3678-85     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Buruli Ulcer / drug therapy*,  microbiology*
Child, Preschool
Drug Combinations
Middle Aged
Mycobacterium ulcerans / drug effects*
Rifampin / therapeutic use*
Streptomycin / therapeutic use*
Treatment Outcome
Young Adult
Grant Support
MR/J01477X/1//Medical Research Council
Reg. No./Substance:
0/Drug Combinations; VJT6J7R4TR/Rifampin; Y45QSO73OB/Streptomycin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  NagZ inactivation prevents and reverts beta-lactam resistance, driven by AmpD and PBP 4 mutations, i...
Next Document:  Fusidic acid resistance rates and prevalence of resistance mechanisms among Staphylococcus spp. isol...